Skip to main content
SpringerLink
Log in

Evidence-based follow-up in renal cell carcinoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The optimal surveillance strategy in renal cell carcinoma after curative resection or ablation is a field of ongoing research. This review discusses the evidence behind routine follow up, duration of follow up, imaging modality and intervals as well as surveillance after local ablative therapy. The recommendations and differences of major guidelines are outlined as well. A risk based approach is advocated taking into account both tumor and patient specific characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Long-term outcomes of follow-up for initially localised clear cell renal cell carcinoma: RECUR database analysis. Eur Urol Focus. 2018; https://doi.org/10.1016/j.euf.2018.02.010.

    Article  PubMed  Google Scholar 

  2. Merrill SB, Sohl BS, Hamirani A, Lehman EB, Lehman KK, Kaag MG, et al. Capturing renal cell carcinoma recurrences when asymptomatic improves patient survival. Clin Genitourin Cancer. 2019;17(2):132–8.

    Article  PubMed  Google Scholar 

  3. Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R, et al. Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urol Oncol. 2018;36(1):11.e1–11.e6.

    Article  Google Scholar 

  4. Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol. 2009;181(5):2044–51.

    Article  PubMed  Google Scholar 

  5. Beisland C, Guðbrandsdottir G, Reisæter LAR, Bostad L, Hjelle KM. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World J Urol. 2016;34(8):1087–99.

    Article  PubMed  Google Scholar 

  6. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174(2):466–72. discussion 472; quiz 801.

    Article  PubMed  Google Scholar 

  7. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174(5):1759–63. discussion 1763.

    Article  PubMed  Google Scholar 

  8. Patard J‑J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the university of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.

    Article  PubMed  Google Scholar 

  9. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–7.

    Article  CAS  PubMed  Google Scholar 

  10. Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78(5):1101–6.

    Article  PubMed  Google Scholar 

  11. Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN project). Eur Urol. 2013;64(3):472–7.

    Article  PubMed  Google Scholar 

  12. Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, et al. Evaluation of the national comprehensive cancer network and American urological association renal cell carcinoma surveillance guidelines. J Clin Oncol. 2014;32(36):4059–65.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Stewart-Merrill SB, Thompson RH, Boorjian SA, Psutka SP, Lohse CM, Cheville JC, et al. Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J Clin Oncol. 2015;33(35):4151–7.

    Article  PubMed  Google Scholar 

  14. Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: results from a European Multicentre database (RECUR). Eur Urol. 2019;75(2):261–4.

    Article  PubMed  Google Scholar 

  15. Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, et al. The usefulness of chest X‑rays for T1a renal cell carcinoma surveillance. J Urol. 2016;196(2):321–6.

    Article  PubMed  Google Scholar 

  16. Chow AK, Kahan AN, Hwang T, Coogan CL, Latchamsetty KC. Should we separate the pulmonary surveillance protocol for postsurgical T1a and T1b renal cell carcinoma? A multicenter database analysis. Urology. 2018;122:127–32.

    Article  PubMed  Google Scholar 

  17. Doornweerd BHJ, de Jong IJ, Bergman LM, Ananias HJK. Chest X‑ray in the follow-up of renal cell carcinoma. World J Urol. 2014;32(4):1015–9.

    CAS  PubMed  Google Scholar 

  18. Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scand J Urol. 2019;53(1):14–20.

    Article  PubMed  Google Scholar 

  19. Platzek I, Zastrow S, Deppe P‑E, Grimm M‑O, Wirth M, Laniado M, et al. Whole-body MRI in follow-up of patients with renal cell carcinoma. Acta Radiol. 2010;51(5):581–9.

    Article  PubMed  Google Scholar 

  20. Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38(2):156–63.

    Article  PubMed  Google Scholar 

  21. Gofrit ON, Orevi M. Diagnostic challenges of kidney cancer: a systematic review of the role of positron emission tomography-computerized tomography. J Urol. 2016;196(3):648–57.

    Article  PubMed  Google Scholar 

  22. Liu Y. The place of FDG PET/CT in renal cell carcinoma: value and limitations. Front Oncol. 2016;6:201.

    PubMed  PubMed Central  Google Scholar 

  23. Shvarts O, Lam JS, Kim HL, Han K, Figlin R, Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol. 2004;172(3):867–70.

    Article  PubMed  Google Scholar 

  24. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol. 2008;179(4):1227–33. discussion 1233–1234.

    Article  PubMed  Google Scholar 

  25. Iannuccilli J, Grand D, Dupuy D, Mayo-Smith W. Percutaneous ablation for small renal masses-imaging follow-up. Semin intervent Radiol. 2014;31(1):50–63.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RJ, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006;176(5):1973–7.

    Article  PubMed  Google Scholar 

  27. Patel U, Sokhi H. Imaging in the follow-up of renal cell carcinoma. AJR Am J Roentgenol. 2012;198(6):1266–76.

    Article  PubMed  Google Scholar 

  28. Thumar AB, Trabulsi EJ, Lallas CD, Brown DB. Thermal ablation of renal cell carcinoma: triage, treatment, and follow-up. J Vasc Interv Radiol. 2010;21(8 Suppl):S233–41.

    Article  PubMed  Google Scholar 

  29. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.

    Article  PubMed  Google Scholar 

  30. Motzer RJ, Jonasch E, Agarwal N, National Comprehensive Cancer Network. Kidney Cancer. 2019;64. Referenced with permission from the NCCN Guidelines® for Kidney Cancer V.2.2020 © National Comprehensive Cancer Network. 2019. www.NCCN.org. Accessed 28 June 2019.

    Google Scholar 

  31. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol. 2013;190:407–16.

    Article  PubMed  Google Scholar 

  32. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–20.

    Article  CAS  PubMed  Google Scholar 

  33. Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006;8(1):1–7.

    PubMed  PubMed Central  Google Scholar 

  34. Williamson TJ, Pearson JR, Ischia J, Bolton DM, Lawrentschuk N. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int. 2016;117(4):555–62.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Montlearstraße 37, 1160, Vienna, Austria

    Karl Mayrhofer MD & Dora Niedersüß-Beke MD, MBA

Authors
  1. Karl Mayrhofer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dora Niedersüß-Beke MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Mayrhofer MD.

Ethics declarations

Conflict of interest

K. Mayrhofer and D. Niedersüß-Beke declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mayrhofer, K., Niedersüß-Beke, D. Evidence-based follow-up in renal cell carcinoma. memo 13, 78–83 (2020). https://doi.org/10.1007/s12254-019-00540-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-019-00540-9

Keywords

Search

Navigation